78 related articles for article (PubMed ID: 38502143)
1. Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple-negative breast cancer cells.
Choi E; Jeon KH; Lee H; Mun GI; Kim JA; Shin JH; Kwon Y; Na Y; Lee YS
Cancer Sci; 2024 Jun; 115(6):2036-2048. PubMed ID: 38613358
[TBL] [Abstract][Full Text] [Related]
2. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
[TBL] [Abstract][Full Text] [Related]
3. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.
Xiong N; Wu H; Yu Z
Front Oncol; 2024; 14():1405491. PubMed ID: 38863622
[TBL] [Abstract][Full Text] [Related]
4. Biocompatible cellulose nanocrystal-based Trojan horse enables targeted delivery of nano-Au radiosensitizers to triple negative breast cancer cells.
Biagiotti G; Cazzoli R; Andreozzi P; Aresta G; Francesco M; Mangini C; di Gianvincenzo P; Tobia C; Recchia S; Polito L; Severi M; Vittorio O; Cicchi S; Moya SE; Ronca R; Albini A; Berti D; Orecchia R; Garibaldi C; Minucci S; Richichi B
Nanoscale Horiz; 2024 May; ():. PubMed ID: 38775782
[TBL] [Abstract][Full Text] [Related]
5. Recent advancements of hydrogels in immunotherapy: Breast cancer treatment.
Mondal J; Chakraborty K; Bunggulawa EJ; An JM; Revuri V; Nurunnabi M; Lee YK
J Control Release; 2024 Jun; 372():1-30. PubMed ID: 38849092
[TBL] [Abstract][Full Text] [Related]
6. Advancements in Biotechnology and Stem Cell Therapies for Breast Cancer Patients.
Dhoundiyal S; Alam MA
Curr Stem Cell Res Ther; 2024; 19(8):1072-1083. PubMed ID: 37815191
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
8. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
Loap P; Loirat D; Berger F; Rodrigues M; Bazire L; Pierga JY; Vincent-Salomon A; Laki F; Boudali L; Raizonville L; Mosseri V; Jochem A; Eeckhoutte A; Diallo M; Stern MH; Fourquet A; Kirova Y
JAMA Oncol; 2022 Dec; 8(12):1802-1808. PubMed ID: 36301572
[TBL] [Abstract][Full Text] [Related]
9. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
Fremd C; Jaeger D; Schneeweiss A
Expert Rev Anticancer Ther; 2019 Jan; 19(1):29-42. PubMed ID: 30351981
[No Abstract] [Full Text] [Related]
10. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
11. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
12. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives.
Kim J; Fahmy V; Haffty BG
Expert Rev Anticancer Ther; 2024 May; 24(5):211-217. PubMed ID: 38502143
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
